Cargando…

Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis

Efforts have been made to identify factors influencing clinical response in patients with atopic dermatitis (AD) treated with dupilumab. A retrospective single-center observational study was carried out by analyzing data from 492 patients aged 12 years and older with moderate-to-severe AD. The study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrucci, Silvia, Casazza, Giovanni, Zussino, Martina, Tavecchio, Simona, Marzano, Angelo V., Tedeschi, Micol
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607560/ https://www.ncbi.nlm.nih.gov/pubmed/37892713 http://dx.doi.org/10.3390/jcm12206575

Ejemplares similares

Skin barrier status during dupilumab treatment in patients with severe atopic dermatitis
por: Ferrucci, Silvia, et al.
Publicado: (2021)

Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
por: Ferrucci, Silvia, et al.
Publicado: (2020)

Asthma improvement in patients treated with dupilumab for severe atopic dermatitis
por: Dubini, Marco, et al.
Publicado: (2023)

Efficacy of Dupilumab on Different Phenotypes of Atopic Dermatitis: One-Year Experience of 221 Patients
por: Tavecchio, Simona, et al.
Publicado: (2020)

Transitory Dissemination of Molluscum Contagiosum in a Patient Treated with Dupilumab for Atopic Dermatitis
por: FERRUCCI, Silvia, et al.
Publicado: (2020)

Emerging Systemic Treatments for Atopic Dermatitis
por: Ferrucci, Silvia Mariel, et al.
Publicado: (2023)

Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Esposito, Maria, et al.
Publicado: (2022)

Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
por: Xu, Xinghua, et al.
Publicado: (2017)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Dupilumab for atopic dermatitis
Publicado: (2019)

Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)

Dupilumab therapy following JAK inhibitor withdrawal in moderate–severe atopic dermatitis
por: Kiely, Lisa, et al.
Publicado: (2022)

Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis
por: Napolitano, Maddalena, et al.
Publicado: (2022)

Rapid response to dupilumab treatment in children with moderate‐to‐severe atopic dermatitis: A case series
por: Votto, Martina, et al.
Publicado: (2022)

Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate‐to‐severe hidradenitis suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
por: Awosika, Olabola, et al.
Publicado: (2018)

COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
por: Ungar, Benjamin, et al.
Publicado: (2022)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
por: MARESCHAL, Adrien, et al.
Publicado: (2020)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice
por: Jang, Dong Hyek, et al.
Publicado: (2020)

Moderate‐to‐severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real‐world experience
por: Stingeni, L., et al.
Publicado: (2022)

Factors Associated with Affective Symptoms and Quality of Life in Patients with Atopic Dermatitis
por: FERRUCCI, Silvia Mariel, et al.
Publicado: (2021)

Effects of dupilumab in type 1 neurofibromatosis coexisting with severe atopic dermatitis()()
por: Chello, Camilla, et al.
Publicado: (2021)

Blood Cells Count Derived Inflammation Indexes as Predictors of Early Treatment Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
por: Zinellu, Angelo, et al.
Publicado: (2023)

Does Monthly Dupilumab Therapy Maintain its Clinical Efficacy in Moderate-to-Severe Atopic Dermatitis?
por: Kim, Su Min, et al.
Publicado: (2021)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: SILVERBERG, Jonathan I., et al.
Publicado: (2021)

Improve the dupilumab therapy evaluation with dermoscopy and high‐frequency ultrasound in moderate‐to‐severe atopic dermatitis
por: Liu, Zhaorui, et al.
Publicado: (2022)

Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment
por: Armstrong, April, et al.
Publicado: (2021)

Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis
por: Maudinet, Adrien, et al.
Publicado: (2019)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
por: Peterson, Danielle M., et al.
Publicado: (2021)

Efficacy and safety of dupilumab in two adolescents with severe atopic dermatitis
por: Giavina-Bianchi, Mara, et al.
Publicado: (2021)

Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer
por: Tanczosova, Milena, et al.
Publicado: (2023)

High dupilumab levels in tear fluid of atopic dermatitis patients with moderate‐to‐severe ocular surface disease
por: Achten, Roselie, et al.
Publicado: (2023)

Alopecia areata after dupilumab for atopic dermatitis
por: Mitchell, Krystal, et al.
Publicado: (2018)

Conjunctivitis in patients with atopic dermatitis treated with dupilumab
por: Ferreira, Sandra, et al.
Publicado: (2020)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
por: Zubek, Amanda E., et al.
Publicado: (2020)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1pavu2b2bskdhfdcoq5o2oprrk